MarketLens

Stock Analysis Investment Ideas

What Does the Ligand-XOMA Deal Mean for the Royalty Aggregator Landscape

4 months ago

SHARE THIS ON:

What Does the Ligand-XOMA Deal Mean for the Royalty Aggregator Landscape

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

What Does SK Hynix's $8 Billion ASML Deal Mean for the Semiconductor Landscape

What Does SK Hynix's $8 Billion ASML Deal Mean for the Semiconductor Landscape

5 months ago

What Does Global Robotics' Latest Acquisition Mean for the Industrial Automation Landscape

What Does Global Robotics' Latest Acquisition Mean for the Industrial Automation Landscape

4 months ago

What Does Santander's Acquisition of Webster Financial Mean for the U.S. Banking Landscape

What Does Santander's Acquisition of Webster Financial Mean for the U.S. Banking Landscape

6 months ago

What Does FERC Approval Mean for the TXNM Energy-Blackstone Deal

What Does FERC Approval Mean for the TXNM Energy-Blackstone Deal

6 months ago

Category

Top Featured Pro Only Stock Analysis Investment Ideas ETFs Crypto

You may also like

Stock News•1 months ago

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

Royalty Pharma appointed Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. He will lead academic outreach and oversee the Translational Prize, joining fr...

Stock News•1 months ago

Biotech's takeover boom may be running out of buyers

Biotech deal value hit $78B in H1 2026, nearly double 2025's full-year $42B total. RBC Capital Markets warns the pace is unlikely to hold, suggesting a slowdown ahead.

Stock News•1 months ago

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Ligand completed its ~$739M acquisition of XOMA Royalty at $39/share, creating a portfolio of over 200 biopharmaceutical royalty assets including VABYSMO and OJEMDA.

Breaking News

Biotech & Pharma

Claude (Anthropic)

Corporate Earnings

Llama (Meta AI)

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

4 weeks ago

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

4 weeks ago

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

4 weeks ago

Top Headlines

Stock News•1 hour ago

AirPods 5 Review: Apple Lowers Prices and Upgrades ANC

Stock News•1 hour ago

Comcast (CMCSA) Suffers a Larger Drop Than the General Market: Key Insights

Stock News•1 hour ago

Why UnitedHealth Group (UNH) Dipped More Than Broader Market Today

Stock News•1 hour ago

Why Vertiv Holdings Co. (VRT) Dipped More Than Broader Market Today

Stock News•1 hour ago

Amazon (AMZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know